28 completed, 6 terminated, 6 unknown, 1 recruiting. 41 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Completed 28, Terminated 6, Unknown 6, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Aprepitant, Placebo - Spinal Fusion, Nausea and Vomiting, Postoperative | Phase 2 | Recruiting | IWK Health Centre | 100 | 2025-03-17 | 2026-04-27 |
| The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs Olanzapine - Nausea, Vomiting | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 43 | 2020-12-01 | 2022-01-21 |
| Low Dose Aprepitant for Patients Receiving Carboplatin Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Terminated | Albert Einstein College of Medicine | 15 | 2018-10-30 | 2023-11-13 |
| Phase 2 Bunionectomy HTX-011 Administration Study HTX-011, Luer Lock applicator, Vial access device - Postoperative Pain | Phase 2 | Completed | Heron Therapeutics | 78 | 2018-10-24 | 2026-03-02 |
| Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis Olanzapine, Aprepitant Pill, Ondansetron - Emesis, Vomiting | Phase 2 | Unknown | Blokhin's Russian Cancer Research Center | 130 | 2018-05-25 | 2018-07-05 |
| Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC Aprepitant - Vomiting, Nausea Post Chemotherapy | Phase 2 | Completed | Chinese Academy of Medical Sciences | 44 | 2018-03-01 | 2020-07-15 |
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Temozolomide, Aprepitant, Minocycline - Glioblastoma | Phase 1 / Phase 2 | Completed | University of Ulm | 10 | 2016-11-01 | 2021-10-05 |
| Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine - Locally Advanced Sarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2016-10-12 | 2021-08-09 |
| Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy Aprepitant, Palonosetron, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting, Lung Cancer | Phase 2 | Unknown | Zhejiang University | 80 | 2015-12-01 | 2015-12-09 |
| Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment Aprepitant, Desloratadine, Placebo of aprepitant - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 138 | 2015-12-01 | 2021-05-18 |
| Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries dexamethasone, Gabapentin, Aprepitant - Postoperative Nausea and Vomiting | Phase 2 / Phase 3 | Completed | Assiut University | 150 | 2015-08-01 | 2016-03-24 |
| Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy FOSAPREPITANT (Emend), Placebo - Non-small Cell Lung Cancer, Vomiting | Phase 2 | Unknown | Ajeet Gajra | 150 | 2015-04-01 | 2015-04-03 |
| Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence aprepitant, Placebo, Manual-guided behavioral counseling - Cannabis Dependence, Alcohol Dependence | Phase 2 | Completed | The Scripps Research Institute | 20 | 2014-09-04 | 2017-08-02 |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide aprepitant, ondansetron - Nausea, Vomiting | Phase 2 | Completed | Katy Peters | 136 | 2014-06-24 | 2018-06-26 |
| Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy Olanzapine, Aprepitant - Chemotherapy Induced Nausea and Vomiting | Phase 2 | Completed | Indiana University | 15 | 2014-02-01 | 2017-03-30 |
| Topical Aprepitant in Prurigo Patients Aprepitant, Placebo - Pruritus | Phase 2 | Completed | LEO Pharma | 20 | 2013-10-01 | 2025-03-10 |
| Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma Fosaprepitant - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Terminated | St. Louis University | 13 | 2013-09-01 | 2018-06-07 |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas TRC102, CT scan, Lomotil - Lymphomas, Solid Tumors | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2013-07-12 | 2024-05-08 |
| Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Aprepitant, Placebo - Gastroparesis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 126 | 2013-04-01 | 2019-05-08 |
| A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) Aprepitant, Placebo to Aprepitant, Ondansetron - Post-operative Nausea, Post-operative Vomiting | Phase 2 | Completed | Merck Sharp & Dohme LLC | 229 | 2013-02-12 | 2018-09-25 |
Showing 20 of 41. Sign in to see all of them.
Vomiting (25) · Nausea (20) · Alcoholism (3) · Neoplasms (3) · Postoperative Nausea and Vomiting (3) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Marijuana Abuse (2) · Pruritus (2) · Alcohol-Related Disorders (1) · Bile Duct Neoplasms (1) · Bunion (1) · Carcinoma, Renal Cell (1)
Merck Sharp & Dohme LLC (3) · Chinese Academy of Medical Sciences (2) · M.D. Anderson Cancer Center (2) · The Scripps Research Institute (2) · Ajeet Gajra (1) · Albert Einstein College of Medicine (1) · Assiut University (1) · Associazione Salentina Angela Serra (1) · Blokhin's Russian Cancer Research Center (1) · Campus Bio-Medico University (1) · GlaxoSmithKline (1) · Hallym University Medical Center (1) · Heron Therapeutics (1) · IWK Health Centre (1) · Indiana University (1)
United States (19) · Canada (4) · China (4) · Italy (3) · Germany (2) · South Korea (2) · Argentina (1) · Austria (1) · Belgium (1) · Chile (1) · Croatia (1) · Czechia (1) · Egypt (1) · Hong Kong (1) · Hungary (1)
Ajeet Gajra, MD FACP (1) · Alice P Chen, M.D. (1) · Arthur Blackstock (1) · Barbara J Mason, Ph.D. (1) · Barbara J. Mason, Ph.D. (1) · Daniele Santini, MD, PhD (1) · David T George, M.D. (1) · Duk Soo Bae, MD, PhD (1) · Edward Chow, MBBS PhD FRCPC (1) · Frank Hamilton, MD, MPH (1) · Gunnar Birgegard, MD, PhD (1) · Hala S Abdel-Ghaffar, MD (1) · Holly Knoderer, MD (1)
PMID 22995650, PMID 16014882, PMID 16918326, PMID 17085262, PMID 17298105, PMID 17522250, PMID 17535226, PMID 18048820, PMID 18181978, PMID 19692680, PMID 19793151, PMID 20067329, PMID 20493771, PMID 20532044, PMID 20544226, PMID 20718754, PMID 20820812, PMID 21039410, PMID 21630130, PMID 21783417, PMID 22141732, PMID 22512843, PMID 22850916, PMID 22870909, PMID 24337621, PMID 24517320, PMID 25409596, PMID 28032216, PMID 29111115, PMID 30381138, PMID 30900392, PMID 31725196, PMID 34620071, PMID 34959641, PMID 36197287, PMID 38396172
R01DA030988 (2), 2009 (1), K01DA025073 (1), U01DK073974 (1), U01DK073975 (1), U01DK073983 (1), U01DK073985 (1), U01DK074007 (1), U01DK074008 (1), U01DK074035 (1)